[1] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China:summary of a report of 72314 cases from the chinese center for disease control and prevention[J]. JAMA, 2020.doi:10.1001/jama.2020.2648.
[2] 阴赪宏, 王超, 汤哲, 等. 146例成人重症SARS的临床分析[J]. 中华急诊医学杂志, 2004, 13(1):12-14.
[3] 郑毅, 李文雄, 黄克武, 等. 重症SARS患者急性期后院内获得性肺炎[J]. 中华医院感染学杂志, 2003, 13(11):85-87+21.
[4] Vanderbeke L, Spriet I, Breynaert C, et al. Invasive pulmonary aspergillosis complicating severe influenza:epidemiology, diagnosis and treatment[J]. Curr Opin Infect Dis, 2018,31(6):471-480.
[5] Schauwvlieghe A, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza:a retrospective cohort study[J]. Lancet Respir Med, 2018,6(10):782-792.
[6] Van de Veerdonk FL, Kolwijck E, Lestrade PP, et al. Influenza-Associated Aspergillosis in Critically Ill Patients[J]. Am J Respir Crit Care Med, 2017,196(4):524-527.
[7] Martin-Loeches I, M JS, Vincent JL, et al. Increased incidence of co-infection in critically ill patients with influenza[J]. Intensive Care Med, 2017,43(1):48-58.
[8] Wauters J, Baar I, Meersseman P, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients:a retrospective study[J]. Intensive Care Med, 2012,38(11):1761-1768.
[9] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study[J]. Lancet, 2020,395(10223):507-513.
[10] Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China:a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5):475-481.
[11] 胡明.直播精华|胡明:武汉市肺科医院ICU重症新冠肺炎诊治经验-阻击新冠权威在线.呼吸界[OL]. 2020-02-11[2020-02-11]. http://www.360doc.com/content/20/0211/09/10128319_891195797.shtml.
[12] 徐凯进, 蔡洪流, 沈毅弘, 等. 2019冠状病毒病(COVID-19)诊疗浙江经验[J]. 浙江大学学报(医学版),2020,49(2):147-157.
[13] McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung[J]. Nat Rev Microbiol, 2014,12(4):252-262.
[14] Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis[J]. Clin Infect Dis, 2012,54(9):1240-1248.
[15] Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis[J]. Clin Infect Dis, 2010,50(12):1559-1567.
[16] Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006[J]. Emerg Infect Dis, 2011,17(10):1855-1864.
[17] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,46(3):327-360.
[18] Ullmann AJ, Cornely OA, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012:developing European guidelines in clinical microbiology and infectious diseases[J]. Clin Microbiol Infect, 2012, 18(Suppl 7):1-8.
[19] Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016,63(4):e1-e60.
[20] Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-beta-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis:systematic review and meta-analysis[J]. J Clin Microbiol, 2012,50(1):7-15.
[21] Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia:a meta-analysis[J]. Clin Microbiol Infect, 2013,19(1):39-49.
[22] 中国成人念珠菌病诊断与治疗专家共识组.中国成人念珠菌病诊断与治疗专家共识[J]. 中国医学前沿杂志(电子版),2020,12(1):35-50.
[23] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis, 2019, doi:10.1093/cid/ciz1008.
[24] Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis:rationale and clinical guidelines for diagnosis and management[J]. Eur Respir J, 2016,47(1):45-68.
[25] Page ID, Richardson M, Denning DW. Antibody testing in aspergillosis-quo vadis[J]? Med Mycol, 2015,53(5):417-439.
[26] Guo Y, Bai Y, Yang C, et al. Evaluation of Aspergillus IgG, IgM antibody for diagnosing in chronic pulmonary aspergillosis:A prospective study from a single center in China[J]. Medicine (Baltimore), 2019,98(16):e15021.
[27] Li H, Rui Y, Zhou W, et al. Role of the Aspergillus-specific IgG and IgM test in the diagnosis and follow-up of chronic pulmonary aspergillosis[J]. Front Microbiol, 2019,10:1438.
[28] Ma X, Wang K, Zhao X, et al. Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis[J]. BMC Infect Dis, 2019,19(1):694.
[29] Ahmad S, Khan Z. Invasive candidiasis:a review of nonculture-based laboratory diagnostic methods[J]. Indian J Med Microbiol, 2012,30(3):264-269.
[30] Li F, Yu X, Ye L, et al. Clinical value of (1,3)-beta-D-glucan, mannan, antimannan IgG and IgM antibodies in diagnosis of invasive candidiasis[J]. Med Mycol, 2019,57(8):976-986.
[31] Mikulska M, Calandra T, Sanguinetti M, et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis:recommendations from the Third European Conference on Infections in Leukemia[J]. Crit Care, 2010,14(6):R222.
[32] Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients[J]. Bone Marrow Transplant, 2012,47(6):846-854.